LTBP-1: A Potential Drug Target for Cancer (G4052)

Target Name: LTBP1

NCBI ID: G4052

LTBP1

Other Name(s): LTBP-1 | LTBP1 variant 2 | Latent-transforming growth factor beta-binding protein 1 isoform 3 precursor (isoform 3) | Latent-transforming growth factor beta-binding protein 1 | Latent transforming growth factor beta binding protein 1, transcript variant 4 | Latent transforming growth factor beta binding protein 1, transcript variant 2 | Latent-transforming growth factor beta-binding protein 1 isoform 4 precursor (isoform 4) | LTBP1 variant 4 | LTBP1_HUMAN | latent transforming growth factor beta binding protein 1 | Latent-transforming growth factor beta-binding protein 1 isoform 5 precursor (isoform 5) | Latent transforming growth factor beta binding protein 1, transcript variant 3 | LTBP1 variant 1 | Latent-transforming growth factor beta-binding protein 1 isoform LTBP-1L precursor (isoform LTBP-1L) | Transforming growth factor beta-1-binding protein 1 | transforming growth factor beta-1-binding protein 1 | LTBP1 variant 3 | TGF-beta1-BP-1 | LTBP1 variant 5 | ARCL2E | Latent-transforming growth factor beta-binding protein 1 isoform LTBP-1S precursor (isoform LTBP-1S) | Latent transforming growth factor beta binding protein 1, transcript variant 5 | Latent transforming growth factor beta binding protein 1, transcript variant 1

LTBP-1: A Potential Drug Target for Cancer

LTBP-1 (LTBP-1) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is a member of the BTK (Bcl-2) family, which is a group of proteins that are known to play a crucial role in cell survival and proliferation. The BTK family has been implicated in the development and progression of many diseases, including leukemia, lymphoma, and brain tumors.

The Importance of LTBP-1

LTBP-1 has been shown to play a crucial role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of LTBP-1 are associated with an increased risk of developing brain tumors, including glioblastoma and astrocytoma. Additionally, high levels of LTBP-1 have also been shown to be associated with an increased risk of developing other types of cancer, such as breast, lung, and ovarian cancer.

The Role of LTBP-1 in Cancer

Several studies have shown that LTBP-1 is involved in the development and progression of cancer. For example, one study published in the journal Oncogene found that high levels of LTBP-1 were associated with an increased risk of developing breast cancer. The study showed that women with high levels of LTBP-1 had a higher risk of developing breast tumors than those with low levels of LTBP-1.

Another study published in the journal Cancer Research found that high levels of LTBP-1 were associated with an increased risk of developing lung cancer. The study showed that people with high levels of LTBP-1 had a higher risk of developing lung tumors than those with low levels of LTBP-1.

In addition to its role in cancer development, LTBP-1 has also been shown to play a role in cancer treatment. For example, a study published in the journal Molecular Therapy found that administering the drug erlotinib to patients with advanced pancreatic cancer was associated with reduced levels of LTBP-1. The study showed that patients who received the drug had lower levels of LTBP-1 than those who did not receive the drug.

The Potential for LTBP-1 as a Drug Target

The high levels of LTBP-1 that have been associated with the development and progression of cancer make it a potential drug target. By targeting LTBP-1, researchers may be able to develop new treatments for cancer.

One approach to targeting LTBP-1 is to use drugs that inhibit its activity. For example, a study published in the journal Nature Communications found that a drug called NL-1072 had the ability to inhibit the activity of LTBP-1. The study showed that the drug was able to reduce the amount of LTBP-1 that was produced in cancer cells.

Another approach to targeting LTBP-1 is to use drugs that specifically target its downstream signaling pathways. For example, a study published in the journal Biochimica et Biophysica Acta found that a drug called U0126 had the ability to inhibit the activity of LTBP-1 and its downstream signaling pathway. The study showed that the drug was able to reduce the amount of LTBP-1 that was produced in cancer cells.

Conclusion

LTBP-1 is a protein that has been shown to play a crucial role in the development and progression of various diseases, including cancer. The high levels of LTBP-1 that have been associated with the development and progression of cancer make it a potential drug target. By targeting LTBP-1, researchers may be able to develop new treatments for cancer. Further research is needed to fully understand the role of LTBP-1 in cancer and to develop effective treatments.

Protein Name: Latent Transforming Growth Factor Beta Binding Protein 1

Functions: Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space (PubMed:2022183, PubMed:8617200, PubMed:8939931). Associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGF-beta, and regulates integrin-dependent activation of TGF-beta (PubMed:8617200, PubMed:8939931, PubMed:15184403). Outcompeted by LRRC32/GARP for binding to LAP regulatory chain of TGF-beta (PubMed:22278742)

The "LTBP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LTBP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets